USE OF BIOMARKER IN THE PREPARATION OF KIT USED IN METHOD FOR EARLY WARNING OF PROGNOSIS RISK IN PATIENT WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

PHARMACOLOGICAL INHIBITION OF MEK CAN IMPROVE OUTCOMES OF HYPERTROPHIC CARDIOMYOPATHY (HCM) IN INDIVIDUALS WITH NOONAN SYNDROME WITH MULTIPLE LENTIGINES (NSML)

LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY UTILIZING THREE ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF

METHODS OF DIAGNOSING ACUTE CIRCULATORY FAILURE

METHOD FOR MEASURING CELL FREE CHROMATIN

METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS

IGFBP7 RATIO FOR HFpEF

BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION

PRESCRIPTION OF REMOTE PATIENT MANAGEMENT BASED ON BIOMARKERS

CLOSED LOOP SYSTEMS AND METHODS FOR MONITORING DIURETIC DOSAGE-REQUIREMENT

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF DILATED CARDIOMYOPATHY AND HEART FAILURE

DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

NOVEL METHOD FOR DETERMINING A CONCENTRATION OF N-TERMINAL PRO-HORMONE BNP (NT-PROBNP) IN A SAMPLE

BIOMARKER IDENTIFICATION FOR IMMINENT AND/OR IMPENDING HEART FAILURE

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE

BIOMARKER

Combined Immunoassay and Magnetic Immunoassay Methods for Extended Range of Sensitivity

LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE

METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS

METHODS AND MATERIALS FOR DETERMINING pGC TARGET DOSAGE

COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE

Cardiovascular Disease

METHOD FOR DIAGNOSIS OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY

HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY

Aptamer for specifically recognizing soluble ST2 protein and application of the same

COMPOSITIONS AND METHODS FOR MONITORING ENPP1 ACTIVITY

METABOLIC BIOMARKERS FOR ASSESSING HEART FAILURE IN A SINGLE VENTRICLE PEDIATRIC SUBJECT

USE OF ENHANCED TBX1 EXPRESSION IN REPAIRING HEART TISSUE INJURY

Inhibitors of the tissue factor-protease activated receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF) and associated or resulting diseases

GALECTIN-3 IMMUNOASSAY

Highly Sensitive System and Method for Analysis of Troponin

BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION

Beta blocker therapy with electrical administration

Device and method for detection of analytes

DEVICE AND METHOD FOR MEASURING THE LEVEL OF BIOMARKERS AND PATHOGENS IN SUBSTANCES

HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNP

METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE

DIAGNOSIS OF STAGE B2 DMVD

ANTIBODIES BINDING SPECIFICALLY TO NT-PROBNP AND USE THEREOF

HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION

Assay for Assessing Heart Failure

ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT

DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS

Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis

FULL-LENGTH CILP AS A BIOMARKER FOR CARDIAC FIBROSIS

Biomarker identification for imminent and/or impending heart failure

ASSESSING AND TREATING ACUTE DECOMPENSATED HEART FAILURE

METHOD FOR DETECTING NUCLEOSOMES CONTAINING HISTONE VARIANTS

DETECTION METHOD OF CIRCULATING BMP10 (BONE MORPHOGENETIC PROTEIN 10)

METHOD FOR PREVENTING, TREATING OR DELAYING HEART FAILURE BY USING NEUREGULIN, AND COMPOSITION

BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE

Methods and compositions for detecting and diagnosing diseases and conditions

METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASE DETECTION AND MANAGEMENT

HEART FAILURE MARKER

Compositions and methods for treating heart failure

USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

PEPTIDE ANTIGENS AND USES THEREOF

Assay for Assessing Heart Failure

Gene Expression Inflammatory Age and Its Uses

PRESCRIPTION OF REMOTE PATIENT MANAGEMENT BASED ON BIOMARKERS

IGFBP7 RATIO FOR HFpEF

MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE

NOVEL ANTI-TROPONINT ANTIBODIES

POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP

MEANS AND METHOD FOR THE EARLY PREDICTION OF POOR NEUROLOGICAL OUTCOME IN OUT-OF-HOSPITAL CARDIAC ARREST SURVIVORS

Protein activity modification

SELENOPROTEIN P IN HEART FAILURE

Highly sensitive particle enhanced assay for the quantification of NT-proBNP

BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE

EXTENDED RANGE IMMUNOASSAY DEVICES WITH IMMUNOSENSOR AND MAGNETIC IMMUNOSENSOR

METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2)

METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND OTHER RELATED DISEASES BY MEASURING RENIN ACTIVITY, PRO-RENIN, PRO-RENIN RECEPTOR LEVELS IN BLOOD

METHOD AND APPARATUS FOR PREDICITING NEUROLOGICAL OUTCOME POST-CARDIAC ARREST

PREDICTING MORTALITY AND DETECTING SEVERE DISEASE

LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY UTILIZING THREE ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF

CIRCULATING BMP10 (BONE MORPHOGENIC PROTEIN 10) IN THE ASSESSMENT OF ATRIAL FIBRILLATION

Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure

CIRCULATING DKK3 (DICKKOPF-RELATED PROTEIN 3) IN THE ASSESSMENT OF ATRIAL FIBRILLATION

Combined immunoassay and magnetic immunoassay methods for extended range of sensitivity

METHOD OF DETECTING HEART FAILURE, DEVICE FOR DETECTING HEART FAILURE, SANDWICH IMMUNOASSAY METHOD, AND COMBINATION OF ANTIBODIES

Compositions and methods relating to a C-terminal peptide of troponin i with activity as a myofilament CA2+ desensitizer

Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening

BAG3 as a target for therapy of heart failure

Anti-troponin T antibodies

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Nourin gene-based RNA molecular network: novel early diagnostic and prognostic biomarkers for coronary artery disease, unstable angina, STEMI/NSTEMI and heart failure

Methods for determining DPP3 and therapeutic methods

BIOMARKERS FOR RISK PREDICTION OF MORTALITY

Device and method for detection of analytes

Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function

METHOD FOR DETECTING NUCLEOSOMES CONTAINING HISTONE VARIANTS

Highly Sensitive System and Method for Analysis of Troponin

Peptides and method for treatment of cardiac arrest

Anti-transthyretin antibodies

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

Methods of detecting transthyretin

Pharmaceutical composition for prevention or treatment of heart failure

METHODS FOR IDENTIFYING WHETHER PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF) EXHIBIT A HYPERCOAGULABLE STATE

METHODS FOR DIAGNOSIS OF EARLY STAGE HEART FAILURE

Method for prediction of response to cardiovascular regeneration based on detecting the amount of biomarkers

TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE

Nourin molecular biomarkers diagnose angina patients with negative troponin

Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof

DUAL RANGE CARDIAC TROPONIN IMMUNOASSAY DEVICES AND METHODS USING IMMUNOSENSOR AND MAGNETIC IMMUNOSENSOR

Use of IGFBP-7 in the assessment of heart failure

METHOD FOR PROGNOSIS OF THE OUTCOME OF PATIENTS WITH HEART FAILURE (HF)

Test apparatus and methods for ST2 cardiac biomarker

GALECTIN-3 IMMUNOASSAY

Methods and compositions for detecting and diagnosing diseases and conditions

CHD risk stratification evaluations for subjects with high levels of large HDL-P

Methods for treating or predicting risk of a ventricular tachyarrhythmia event

Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients

DETECTION AND TREATMENT OF DILATED CARDIOMYOPATHY IN THE DOBERMAN PINSCHER

ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE

Antibodies recognizing genetic variants of NT-proBNP

Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Automated septal defect detection in cardiac computed tomography images

IGFBP7 for diagnosing diastolic dysfunction

USE OF sCD14 OR ITS FRAGMENTS OR DERIVATIVES FOR RISK STRATIFICATION, DIAGNOSIS AND PROGNOSIS

Protein activity modification

Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof

Method for predicting severity and prognosis of cardiovascular disease

Antibodies to TTR and methods of use

HISTONES AND/OR PROADM AS MARKERS INDICATING ORGAN DYSFUNCTION

Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2

CIRCULATING ESM-1 (ENDOCAN) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND/OR STROKE

Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)

Marker for statin treatment stratification in heart failure

METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS

PROTEIN ACTIVITY MODIFICATION

METHOD FOR DETECTING NUCLEOSOMES CONTAINING HISTONE VARIANTS

DIAGNOSIS OF CARDIOVASCULAR DISEASE

SIGNAL BIOMARKERS

Therapies for cardiomyopathy

Medical use of CREG protein

Automated septal defect detection in cardiac computed tomography images

MEANS AND METHODS FOR DIFFERENTIATING BETWEEN HEART FAILURE AND PULMONARY DISEASE IN A SUBJECT

Sumoylation of Serca2A and Cardiovascular Disease

Predicting mortality and detecting severe disease

Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure

Compositions and methods for detecting, treating and preventing diseases and disorders

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

USE OF CD146 AS A MARKER OF THE VASCULAR WALL TENSION

Methods of detection and treatment for cardiovascular disease and foot wounds

METHOD FOR PROGNOSING ADVERSE CARDIOVASCULAR OUTCOME IN PATIENTS WITH CORONARY ARTERY DISEASES

Peptides and method for treatment of cardiac arrest

Methods of treating a subject having heart failure that include detecting levels of galectin-3 and soluble ST2

Device and method for detection of analytes

P75antagonists and treatment of acute and chronic cardiac disease

Buccal cell diagnosis of arrhythmogenic cardiomyopathy (ACM)

Method for detecting plasminogen activator inhibitor-1 in a sample

MEANS AND METHODS FOR DIAGNOSING CARDIAC DISEASE IN A SUBJECT

IL1RL-1 as a cardiovascular disease marker and therapeutic target

NAP-2 polypeptides and methods for modulating immune system activity in heart tissue

Biomarkers to improve prediction of heart failure risk

Future cardiac event biomarkers CCL3, CCL5, and CCL18

Biomarkers for the detection of acute rejection in heart transplantation

Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor

Combined immunoassay and magnetic immunoassay methods for extended range of sensitivity

Extended range immunoassay devices with immunosensor and magnetic immunosensor

METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE

Methods for Treatment with Bucindolol Based on Genetic Targeting

METHODS FOR TREATING CARDIOVASCULAR DISEASES

Diagnostic of heart failure

Highly Sensitive System and Methods for Analysis of Troponin

Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction

RISK ASSESSMENT FOR ANTIBIOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN

13+/17+ BIN1 expression as a marker of cardiac disorders

GALECTIN-3 IMMUNOASSAY

PROGNOSIS OF ADVERSE EVENTS IN PATIENTS WITH SUSPECTED CHRONIC HEART FAILURE

BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)

SYSTEMS AND METHODS OF DISEASE MODELING USING STATIC AND TIME-DEPENDENT HYDROGELS

Compositions and methods for treating heart failure

Means and Methods for Diagnosing Heart Failure in a Subject

Markers Associated With Arteriovascular Events And Methods Of Use Thereof

Neprilysin as heart failure prognostic marker

Methods for assessing differential risk for developing heart failure

Biomarkers for risk prediction of mortality

MEANS AND METHODS FOR DIAGNOSING HEART FAILURE ON THE BASIS OF CHOLESTEROL PARAMETERS, SPHINGOMYELINS AND/OR TRIACYLGLYCEROLS

Method for detecting cardiac failure patient

LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY UTILIZING THREE ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF

Methods for the treatment of cardiovascular fibrosis

Methods for treating or predicting risk of a ventricular tachyarrhythmia event

Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening

METHODS AND COMPOSITIONS FOR MONITORING HEART FAILURE

Health test for a broad spectrum of health problems

Predicting mortality and detecting severe disease

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS

NEW MARKERS FOR THE ASSESSMENT OF AN INCREASED RISK FOR MORTALITY

Buccal cell diagnosis of arrhythmogenic cardiomyopathy (ACM)

Antibodies to TTR and Methods of Use

IN VITRO DIAGNOSTIC FOR MODEL-BASED THERAPY PLANNING

BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY

CHD risk stratification evaluations for subjects with high levels of large HDL-P

METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE

Use of IGFBP-7 in the assessment of heart failure

BAG3 as a target for therapy of heart failure

Anti-transthyretin antibodies

Sumoylation of SERCA2a and cardiovascular disease

Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP

IGFBP7 for diagnosing diastolic dysfunction

Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof

Methods of Using Interleukin-10 for Treating Diseases and Disorders

PROTEIN ACTIVITY MODIFICATION

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Biomarkers of mineralocorticoid receptor activation

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

Prognosis of adverse events in patients with suspected chronic heart failure

Methods of treating or selecting a treatment for a subject having heart failure that include detecting levels of galectin-3 and soluble ST2

Method for detecting nucleosomes containing histone variants

BIOMARKERS TO IMPROVE PREDICTION OF HEART FAILURE RISK

Assessing renal structural alterations and outcomes

LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION

MEANS AND METHODS FOR DIAGNOSING HEART FAILURE IN A SUBJECT

Using nucleic acids encoding NAP-2 and TGF-alpha polypeptides to improve cardiac function

Highly sensitive system and method for analysis of troponin

Methods and compositions for detecting and diagnosing diseases and conditions

Marker for statin treatment stratification in heart failure

Test apparatus and methods for ST2 cardiac biomarker

Means and methods for diagnosing heart failure in a subject

USE OF ALPHA-CRYSTALLIN B (CRYAB) IN THE ASSESSMENT OF HEART FAILURE

Biomarker of rehospitalization after heart failure

THERAPIES FOR CARDIOMYOPATHY

METHODS OF DETERMINATION OF ACTIVATION OR INACTIVATION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AND BRAIN NATRIURETIC PEPTIDE (BNP) HORMONAL SYSTEMS

Methods for Predicting Cardiovascular Mortality Risk

METHODS FOR TREATMENT OF CARDIOMYOPATHY

Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample

BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF

HSP90-targeted cardiac imaging and therapy

Nucleic acids encoding FHL1 mutations associated with novel X-linked muscular myopathies and methods of screening a subject

DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE

ASSESSING SUSCEPTIBILITY TO CARDIAC INTERVENTION, SUSCEPTIBILITY TO THERAPY FOR HEART FAILURE, RISK OF MORTALITY OR FURTHER CARDIOVASCULAR EVENTS, AND RISK OF SUBSEQUENT PULMONARY EMBOLISM IN RELEVANT PATIENTS BASED ON DETERMINATIONS OF GDF-15, NATRIURETIC PEPTIDE, CARDIAC TROPONIN OR COMBINATIONS THEREOF

METHODS FOR TREATING CARDIOVASCULAR DISEASES

Signal biomarkers

Markers associated with arteriovascular events and methods of use thereof

USE OF sCD14 OR ITS FRAGMENTS OR DERIVATIVES FOR RISK STRATIFICATION, DIAGNOSIS AND PROGNOSIS

MCAM as a biomarker for fluid homeostasis

Sumoylation of SERCA2a and Cardiovascular Disease

Method to determine treatment of acute heart failure

USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE

ASSESSING RENAL STRUCTURAL ALTERATIONS AND OUTCOMES

METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING

BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE

Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment

Isolated cardiac stem cells and methods of their use

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

Method for the treatment of cardiovascular fibrosis

DIAGNOSIS AND TREATMENT OF AUTOANTIBODY-MEDIATED HEART DISEASE

Diagnostic of Heart Failure

Mutations In Calmodulin Genes

Compositions and methods for detecting, treating and preventing diseases and disorders

Methods for treatment of cardiovascular disease

METHODS AND COMPOSITIONS FOR MONITORING HEART FAILURE

Means and methods for diagnosing and monitoring heart failure in a subject

1L1RL-1 as a cardiovascular disease marker and therapeutic target

BAG3 as biochemical serum and tissue marker

Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein

Method for Predicting the Risk of Getting a Cardiovascular Event in a Female Subject

Prognosis of adverse events in patients with suspected chronic heart failure

Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure

Fractional C-reactive protein (fracCRP) antibodies and assays

POLYPEPTIDE MARKERS FOR DIAGNOSIS AND ASSESSMENT OF HEART FAILURE

Device and method for detection of analytes

METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2

Biomarkers of oxidative stress

METHODS FOR THE DETECTION AND THE TREATMENT OF DIASTOLIC DYSFUNCTION

PEPTIDIC INHIBITOR OF SIGNAL TRANSMISSION FROM G-ALPHA-S TO G-ALPHA-I-COUPLED RECEPTOR CASCADES

MULTILEVEL ANALYTE ASSAY

CONGESTIVE HEART FAILURE BIOMARKERS

DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK

Transcriptomic biomarkers for individual risk assessment in new onset heart failure

Bin1 as a prognostic marker in cardiovascular disease

Use of GSTP1

Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment

Diagnosis, Prevention and Treatment of Disorders Characterized by Undesirable Cell Proliferation

Activation of sodium potassium ATPase

PON1 as a marker for heart failure

Methods of identifying FHL1 mutations associated with novel X-linked muscular myopathies

KIT FOR DIAGNOSING CARDIOMYOPATHY AND METHOD FOR PREDICTING CARDIOMYOPATHY

Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease

Biomarkers for sensitive detection of statin-induced muscle toxicity

Method of producing a positive inotropic effect using an antibody that binds sodium potassium atpase

Pharmaceutical composition comprising CCN5 for reducing cardiac fibrosis in a subject in need thereof

Nitrated cardiac troponin I as a biomarker of cardiac ischemia

Biomarkers for pneumonia and acute decompensated heart failure

Highly sensitive system and method for analysis of troponin

Body fluid BIN1 as a marker of cardiac health

Highly sensitive biomarker panels

Diagnostic test for cardiomyopathy

Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems

Method for increasing natriuresis or diuresis by isoforms of brain natriuretic peptide

Perlecan as a biomarker for renal dysfunction

Methods of diagnosing and treating heart failure

Composition comprising an angiopoietin-4 fragment

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION